Candesartan in the treatment of hypertension and heart failure

Česká verzia

Authors: J. Vítovec; J. Špinar
Published in the journal: Kardiol Rev Int Med 2012, 14(4): 258-261
Category:

Summary

Candesartan is a modern AT1 receptor blocker for angiotensin II – sartans. It has favourable pharmacokinetic as well as pharmacodynamic properties. It has shown efficacy in terms of a reduction in morbidity and mortality resulting from such diseases in many clinical trials with respect to both hypertension and heart failure. A brief overview of the pharmacological effects and results of clinical trials (SCOPE, TROPHY, RESOLVED and CHARM) is presented.

Keywords:
candesartan – hypertension – heart failure

Zdroje

1. Vítovec J, Špinar J. Farmakoterapie kardiovaskulárních onemocnění. 2. vyd. Praha: Grada 2004: 248.

2. Slíva J. Candesartan v léčbě kardiovaskulárních onemocnění. Farmakoterapie 2012; 8: 118–122.

3. Trial Results Center. Table summary of clinical trials for candesartan. Available from: www.trialresultscenter.org/DR5-candesartan%20clinical%20trials.htm.

4. Lithell H, Hansson L, Skoog I et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21: 875–886.

5. Julius S, Nesbitt SD, Egan BM et al. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 2006; 354: 1685–1697.

6. McKelvie RS, Yusuf S, Pericak D et al. Comparison of candesartan, enalapril and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 1999; 100: 1056–1064.

7. Pfeffer MA, Swedberg K, Granger CB et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362: 759–766.

8. McMurray JJ, Östergren J, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362: 767–771.

9. Granger CB, McMurray JJ, Yusuf S et al. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function and intolerant to angiotensin-converting-enzyme inhibitors: the CHARM--Alternative trial. Lancet 2003; 362: 772–776.

10. Yusuf S, Pfeffer MA, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362: 777–781.

11. SÚKL ČR. Příbalová studie Candesartanu. Dostupné na: www.sukl.cz/download/pil/PI25209.pdf.

12. Cernes R, Mashavi M, Zimlichman R. Differential clinical profile of candesartan compared to other angiotensin receptor blockers. Vasc Health Risk Manag 2011; 7: 749–759.